Last reviewed · How we verify
RO5323441
At a glance
| Generic name | RO5323441 |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- 89Zr-RO5323441 PET Imaging in Glioblastoma (PHASE2)
- Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours (PHASE1)
- A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma (PHASE1)
- A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1) (PHASE2)
- A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME) (PHASE2)
- A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma (PHASE1)
- A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma (PHASE1)
- A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RO5323441 CI brief — competitive landscape report
- RO5323441 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI